<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431688</url>
  </required_header>
  <id_info>
    <org_study_id>KangdongSHH</org_study_id>
    <nct_id>NCT03431688</nct_id>
  </id_info>
  <brief_title>Tailored Therapy for Clarithromycin-Resistant H. Pylori</brief_title>
  <official_title>Efficacy Comparison of Metronidazole-based Triple and Bismuth-based Quadruple Therapy for Clarithromycin Resistant-Helicobacter Pylori Infection: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangdong Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangdong Sacred Heart Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure.
      Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has
      been studied recently, however, there have been few studies comparing treatment regimen in
      patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin
      resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline,
      metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin)
      regimen in patient with clarithromycin-resistant H. pylori.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori eradication rate</measure>
    <time_frame>14 days</time_frame>
    <description>H. pylori eradication rate</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>PAM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with PPI, metonidazole, amoxicillin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with PPI, metonidazole, bismuth, tetracyclin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAM</intervention_name>
    <description>treatment with PPI, metonidazole, amoxicillin</description>
    <arm_group_label>PAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBMT</intervention_name>
    <description>treatment with PPI, metonidazole, bismuth, tetracyclin</description>
    <arm_group_label>PBMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  peptic ulcer disease

          -  H. pylori gastritis

          -  low grade MALT lymphoma

        Exclusion Criteria:

          -  history of gastric cancer surgery

          -  severe comorbidity (ESRD, LC)

          -  hypersensitivity to drug

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangdong Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Shin, Woon Geon</investigator_full_name>
    <investigator_title>Woon Geon Shin</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

